Cite
Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease.
MLA
Modi, Badri, et al. “Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease.” Biology of Blood & Marrow Transplantation, vol. 25, no. 2, Feb. 2019, pp. 265–69. EBSCOhost, https://doi.org/10.1016/j.bbmt.2018.09.003.
APA
Modi, B., Hernandez-Henderson, M., Yang, D., Klein, J., Dadwal, S., Kopp, E., Huelsman, K., Mokhtari, S., Ali, H., Malki, M. M. A., Spielberger, R., Salhotra, A., Parker, P., Forman, S., & Nakamura, R. (2019). Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease. Biology of Blood & Marrow Transplantation, 25(2), 265–269. https://doi.org/10.1016/j.bbmt.2018.09.003
Chicago
Modi, Badri, Michael Hernandez-Henderson, Dongyun Yang, Jeremy Klein, Sanjeet Dadwal, Erin Kopp, Karen Huelsman, et al. 2019. “Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease.” Biology of Blood & Marrow Transplantation 25 (2): 265–69. doi:10.1016/j.bbmt.2018.09.003.